VT02956

VT02956

V659222-5mg

5mg

-20°C储存

超低温冰袋运输

VT02956 is a LATS inhibitor ( IC 50 : 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids. IC50& Target:IC50: 0.76 nM for LATS1, 0.52 nM for LATS2 In Vitro:VT02956 (2 μM, 0-30 min) reduces YAP/TAZ phosphorylation in HEK293A cells and 4T1 cells. VT02956 (2 μM, 2 days) reduces ERα and its target genes TFF1 and GREB1 in breast tumor organoids BTO-02. VT02956 (2 μM, 4 days) inhibits the proliferation o Biological Activity:VT02956 is a LATS inhibitor ( IC 50 : 0.76u2009nM for LATS1, 0.52u2009nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids.

C22H23N5O

373.45 g/mol

NCC1CCN(CC1)C2=NC(C3=CC=NC=C3)=NC4=C2C=CC=C4C#CCO